Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 67%
Sell 17%
Strong Sell 0%

Bulls say

Amphastar Pharma is experiencing top-line and bottom-line misses in recent quarters due to weak performance of its flagship product, Baqsimi, which is facing intense pricing pressure and higher pharmacy discounts. Despite taking measures like a recent price increase, Baqsimi sales are expected to remain flat or grow only marginally, leading to a revision of sales growth expectations for the year. Additionally, the company's overall revenue growth for 2026 is expected to be in the mid to high-single digits.

Bears say

Amphastar Pharma is facing several challenges, including pricing headwinds and competitive headwinds in the generics business. Despite having a strong pipeline with potential growth opportunities, the visibility of when these opportunities will materialize is unclear, leading to uncertainty about top-line and EBITDA growth. With Baqsimi sales declining, potential new product launches not expected until 2027, and the company's future success dependent on pipeline development, it is clear why the analyst has a negative outlook on Amphastar Pharma's stock.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.